TVB-2640
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
KRAS Gene Mutation
Conditions
KRAS Gene Mutation
Trial Timeline
Sep 11, 2019 → Dec 1, 2026
NCT ID
NCT03808558About TVB-2640
TVB-2640 is a phase 2 stage product being developed by Sagimet Biosciences for KRAS Gene Mutation. The current trial status is active. This product is registered under clinical trial identifier NCT03808558. Target conditions include KRAS Gene Mutation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04906421 | Phase 2 | Completed |
| NCT03808558 | Phase 2 | Active |
| NCT02223247 | Phase 1 | Completed |
Competing Products
20 competing products in KRAS Gene Mutation